Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company that regularly issues news updates about its progress in developing therapies for autoimmune, inflammatory, and other immune-mediated diseases. The company’s announcements frequently focus on its lead program, SL-325, a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to target the clinically validated DR3/TL1A pathway in inflammatory bowel disease (IBD) and related conditions.
News about Shattuck often covers key clinical and regulatory milestones for SL-325, including Investigational New Drug (IND) submissions, IND clearance, initiation of Phase 1 clinical trials in healthy volunteers, and dosing of the first participants. The company also reports on preclinical data for SL-325, such as high-affinity binding to DR3, potent inhibition of TL1A binding, and favorable safety and receptor occupancy findings in non-human primate studies.
Investors following STTK can also expect updates on Shattuck’s broader DR3-focused pipeline, including multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and another biologically relevant target for IBD. Financing news is another recurring theme, with press releases detailing private placements, expected use of proceeds to advance SL-325 through Phase 1 and planned Phase 2 trials, and the company’s views on its cash runway.
Additional news items highlight Shattuck’s participation in medical and investor conferences, key opinion leader panels on DR3/TL1A biology and IBD, and changes to its Board of Directors associated with major financings. For readers tracking STTK, this page provides a centralized view of Shattuck’s clinical progress, scientific presentations, capital-raising activities, and governance developments as disclosed in its public communications.
Shattuck Labs (NASDAQ: STTK) reported Q4 and full-year 2025 results and program updates. As of Dec 31, 2025 cash and short-term investments were $78.1M; preliminary Feb 28, 2026 cash was $94.5M after $21.4M ATM sales. Q4 R&D fell to $9.1M (Q4 2024: $15.4M); full‑year R&D was $35.3M (2024: $67.2M). Net loss improved to $48.8M for 2025 (2024: $75.4M).
Clinical: Phase 1 SL-325 trial is nearly complete with data expected in Q2 2026; Phase 2 in Crohn’s disease is planned to begin in Q3 2026, subject to positive Phase 1 data and regulatory alignment. Lead bispecific entered IND-enabling activities.
Shattuck Labs (NASDAQ: STTK) announced CEO Taylor Schreiber, M.D., Ph.D., will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:10 AM ET in Boston and hold one-on-one meetings at the Leerink Partners 2026 Global Health Care Conference March 10-11 in Miami.
Live audio webcasts will be available via the company's Investor Relations website, with replay accessible for about 30 days after each presentation.
Shattuck Labs (NASDAQ: STTK) will present a prerecorded fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 at 2:00 PM ET. Presenters include Taylor Schreiber, M.D., Ph.D. (CEO), Andrew R. Neill (CFO), and Michael Choi, M.D. (VP Clinical Development).
A replay of the prerecorded presentation will be available on the company’s Events and Presentations webpage starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date.
Shattuck Labs (NASDAQ: STTK) granted inducement equity awards on Dec 10, 2025 to a newly hired non-executive officer under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options to purchase 206,000 shares at an exercise price of $3.23 per share, with a maximum term of 10 years. Vesting is 25% on Nov 17, 2026 and the remainder vests in equal monthly installments over the following 36 months. The awards were granted outside the Company’s 2020 Equity Incentive Plan but are generally subject to the same terms and were approved by the independent Compensation Committee.
Shattuck Labs (NASDAQ: STTK) announced management will participate in multiple investor conferences in December 2025. CEO Taylor Schreiber, M.D., Ph.D. will present at the Piper Sandler 37th Annual Healthcare Conference on Dec 2, 2025 at 10:10 AM ET in New York and will take part in a fireside chat at the Evercore ISI 8th Annual HealthCONx Conference on Dec 4, 2025 at 8:20 AM ET in Coral Gables, plus one-on-one meetings on Dec 3–4. Webcast links will be provided and replays will be available on the company’s Events and Presentations page for up to 30 days after each presentation.
Shattuck Labs (NASDAQ: STTK) reported Q3 2025 results and business highlights on Nov 6, 2025. Key points: IND clearance for lead candidate SL-325 in August 2025; first participants dosed in the Phase 1 SAD portion in Q3 2025; enrollment for SAD and MAD expected complete by Q2 2026 with initial data expected by Q2 2026. Shattuck closed a private placement of up to $103 million in August 2025 and says proceeds, assuming full exercise of warrants, are expected to fund operations into 2029. Q3 2025 financials: cash and short-term investments of $86.1M, R&D expense $7.6M, G&A $4.1M, and net loss $10.1M (or $0.14 per share).
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors, has announced its participation in an upcoming panel discussion following the United European Gastroenterology Week (UEGW) Conference 2025.
The panel will be moderated by Wedbush Securities analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., featuring KOL Dr. Marla Dubinsky from Mount Sinai Health System. Taylor Schreiber, M.D., Ph.D., Shattuck's CEO, will represent the company at the event scheduled for October 8, 2025, from 10:00 AM to 12:00 PM EST.
Shattuck Labs (NASDAQ: STTK) has announced the closing of a significant private placement of up to $103 million, led by OrbiMed. The funding, assuming full exercise of common stock warrants, is expected to support operations into 2029 and advance SL-325, their novel DR3 blocking antibody, through multiple Phase 2 clinical trials focusing on Inflammatory Bowel Disease (IBD).
The company has also strengthened its Board of Directors with two key appointments: Dr. Daniel Baker, former VP of Immunology at Johnson & Johnson/Janssen, and Dr. Mona Ashiya, Member at OrbiMed. These appointments coincide with the departure of four existing board members, marking Shattuck's strategic repositioning as an immunology and inflammation-focused organization.
Shattuck Labs (NASDAQ: STTK) announced that its Investigational New Drug (IND) application for SL-325, a potentially first-in-class DR3 antagonist antibody for treating Inflammatory Bowel Disease (IBD), is now in effect with the FDA.
The company plans to initiate its Phase 1 clinical trial in Q3 2025, with expected completion in Q2 2026. The trial will be a randomized, double-blind, placebo-controlled study evaluating single and multiple ascending doses in healthy volunteers. The company's financial position is strengthened by cash reserves and anticipated proceeds of up to $103 million from a recent private placement, expected to fund operations into 2029.
Shattuck Labs (NASDAQ: STTK) reported Q2 2025 financial results and business updates. The company submitted an IND application for SL-325, their first-in-class DR3 blocking antibody for IBD treatment, with FDA clearance expected in Q3 2025. The Phase 1 clinical trial is set to begin in Q3 2025.
Financial highlights include cash position of $50.5 million as of June 30, 2025, and an oversubscribed private placement expected to provide up to $103 million in additional funding. Q2 2025 showed improved financials with net loss of $12.5 million ($0.24 per share), compared to $21.6 million ($0.42 per share) in Q2 2024. The combined funding is expected to support operations into 2029.